Cambium Bio Limited has released a press release.
FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Cambium Bio Successfully Closes A$3.0M Financing Round
- Trading Halt
- Cambium 4E and Annual Report
- Notice of General Meeting/Proxy Form
- Response to ASX Aware Query
Later from Cambium Bio
- Half Year Report (December 2024)Cambium Bio Limited Half Year Report (December 2024) (Feb 27, 2025Feb 27, 2025)
- Cambium Bio Raises A$2.12 million
- Placement Participant Update
- FY25 Appendix 4E and Annual Report
- Cambium Bio Signs US$2.0M plus Licensing Deal
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio